Acquisition Opportunity FLUIDDA was acquired by Banook Group in November 2025, signaling enterprise-level validation and potential cross-sell opportunities with Banook's global clinical trial and data collection capabilities to expand market reach and service adoption.

FRI Leadership As a pioneer in Functional Respiratory Imaging with capabilities in computational fluid dynamics, FLUIDDA offers unique imaging biomarkers that can complement or de-risk respiratory drug development programs, offering a compelling differentiator for CRO partnerships and trial design optimization.

Strategic Partnerships Recent collaborations with Cereno Scientific, Gossamer Bio, and Nanopharm demonstrate FLUIDDA’s integration into translational and clinical research pipelines, presenting ongoing collaboration channels for co-development studies, asset evaluation, and expansion into PAH and inhalation therapies.

Scalable CRO Offering FLUIDDA provides a full CRO service from protocol writing to advanced image data analysis, backed by a multidisciplinary team. This positions them as a one-stop partner for pharmacometric imaging endpoints, potentially appealing to sponsors seeking streamline in imaging studies.

Growth Potential With reported revenue in the multi-million range and a specialized imaging tech stack (Kubernetes, MongoDB, PostgreSQL, etc.), FLUIDDA targets mid-sized to large pharma and biotech clients seeking sensitive outcome measures, presenting upsell opportunities in larger trial programs and long-term imaging analytics contracts.